Aksoy Asude, Artas Gokhan, Kuloglu Tuncay, Koc Mustafa
Department of Medical Oncology, Firat University Faculty of Medicine, Elazig, Turkiye.
Department of Pathology, Firat University Faculty of Medicine, Elazig, Turkiye.
North Clin Istanb. 2023 Jun 20;10(3):314-321. doi: 10.14744/nci.2022.49260. eCollection 2023.
The balance between malignant tumor cells and the connective tissue surrounding them determines the aggressiveness of the tumor. We aimed to understand the effects of mesothelin (MSLN) and fibulin1 (FBLN1) expressions on survival in pancreas ductal adenocarcinoma (PDCA), and also whether these proteins have prognostic value for PDCA.
Of 80 patients in total, 40 who underwent the Whipple procedure for diagnosed PDCA between 2009 and 2016, and 40 patients with diagnosed pancreatitis as the control group, were included in the present study. Immunohistochemically, MSLN, and FBLN1 expressions were evaluated retrospectively. We assessed the relationship between the degree of MSLN, FBLN1 expression, clinical-pathological features, and survival rates in PDCA cases.
The median follow-up duration was 11.4 (3-41) months. All of the patients for MSLN and FBLN1 were immune reactive. We detected a significant difference in MSLN expression between patients with PDCA and control groups, but not in FBLN1 expression. MSLN, FBLN1 expressions were categorized as lower-higher (L/H) groupings. There was no difference in the median overall survival (OS) of patients in the MSLN groups. The L-FBLN1 group had a median OS of 18 months (95% CI: 9.51-26.48) versus 14 months (95% CI: 13.021-14.97) in the H-FBLN1 group (interconnective tissue) (p=0.035). According to Kaplan-Meier analysis, L-FBLN1 expression in the tumor microenvironment was associated with longer survival in PDCA. The FBLN1 expression in the tumor microenvironment was shown to be significantly inversely related to OS (p=0.05).
The FBLN1 expression, which is in the tumor microenvironment of PDCA, may serve as a prognostic biomarker.
恶性肿瘤细胞与其周围结缔组织之间的平衡决定了肿瘤的侵袭性。我们旨在了解间皮素（MSLN）和纤连蛋白1（FBLN1）表达对胰腺导管腺癌（PDCA）患者生存的影响，以及这些蛋白对PDCA是否具有预后价值。
本研究共纳入80例患者，其中40例于2009年至2016年间因确诊PDCA接受了Whipple手术，40例确诊为胰腺炎的患者作为对照组。采用免疫组织化学方法对MSLN和FBLN1的表达进行回顾性评估。我们评估了PDCA病例中MSLN、FBLN1表达程度、临床病理特征与生存率之间的关系。
中位随访时间为11.4（3 - 41）个月。所有患者的MSLN和FBLN1均呈免疫反应性。我们检测到PDCA患者与对照组之间MSLN表达存在显著差异，但FBLN1表达无差异。MSLN、FBLN1表达分为低 - 高（L/H）分组。MSLN各分组患者的中位总生存期（OS）无差异。低FBLN1组的中位OS为18个月（95%CI：9.51 - 26.48），而高FBLN1组（结缔组织）为14个月（95%CI：13.021 - 14.97）（p = 0.035）。根据Kaplan - Meier分析，肿瘤微环境中低FBLN1表达与PDCA患者更长的生存期相关。肿瘤微环境中的FBLN1表达与OS呈显著负相关（p = 0.05）。
PDCA肿瘤微环境中的FBLN1表达可能作为一种预后生物标志物。
